** Shares of drugmaker AbbVie ABBV.N rise 2.7% to $185.3 premarket
** AbbVie raises its 2025 profit forecast after better-than-expected sales of its newer immunology drugs Skyrizi and Rinvoq help it beat quarterly earnings expectations
** Company expects its annual adjusted profit to be between $12.09 and $12.29 per share, up from its previous estimate of $11.99 to $12.19
** ABBV earns adj. Q1 profit of $2.46 per share, compared with analysts' average expectation of $2.38
** As of last close, ABBV had risen 1.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。